Pharmacokinetics and Pharmacodynamics Practice Questions

Q: A young male presents with severe asthma. The pharmacokinetics of theophylline include the following parameters: Vd = 35 L; CL = 48 mL/min; half-life = 8 hours. If an intravenous infusion of theophylline is started at a rate of 0.48 mg/min, how long will it take to reach 93.75% of the steady state concentration?

Approximately 32 hours. **Explanation:** The core concept tested here is the **relationship between half-life ($t_{1/2}$) and the time required to reach steady-state concentration ($C_{ss}$)** during a continuous drug infusion. 1. **Why Option D is Correct:** In pharmacokinetics, the approach to steady state is a first-order process. It is a high-yield rule that the time taken to reach steady state depends **only on the half-life** of the drug, not on the dose or infusion rate. * After 1 $t_{1/2}$: 50% of $C_{ss}$ is reached. * After 2 $t_{1/2}$: 75% of $C_{ss}$ is reached. * After 3 $t_{1/2}$: 87.5% of $C_{ss}$ is reached. * **After 4 $t_{1/2}$: 93.75% of $C_{ss}$ is reached.** * After 5 $t_{1/2}$: 96.8% (~97%) of $C_{ss}$ is reached. Given the half-life ($t_{1/2}$) is **8 hours**, the time to reach 93.75% is $4 \times 8 \text{ hours} = \mathbf{32 \text{ hours}}$. 2. **Why Other Options are Incorrect:** * **Option A (48 mins):** This is a distractor using the Clearance (CL) value. * **Option B (5.8 hours):** This is a distractor using the $V_d$ or incorrect math. * **Option C (8 hours):** This represents only 1 half-life (50% of $C_{ss}$), which is insufficient. 3. **Clinical Pearls for NEET-PG:** * **Steady State:** It takes approximately **4 to 5 half-lives** to reach clinical steady state. * **Loading Dose:** If a rapid effect is needed (like in acute asthma), a **loading dose** ($LD = V_d \times \text{Target } C_p$) is given to bypass the delay in reaching steady state. * **Elimination:** Similarly, it takes 4–5 half-lives for a drug to be completely eliminated from the body after stopping the infusion. * **Theophylline:** It has a narrow therapeutic index; toxicity can occur if clearance is decreased (e.g., by Cimetidine or Erythromycin).

Q: The dose of which antibiotic need not be altered in renal failure?

Erythromycin. **Explanation:** The primary factor determining whether a drug requires dose adjustment in renal failure is its **route of elimination**. Drugs that are primarily excreted unchanged by the kidneys require dose reduction to prevent toxicity, whereas drugs metabolized by the liver or excreted via bile do not. **Why Erythromycin is correct:** Erythromycin is a macrolide antibiotic that is primarily metabolized by the **liver** and excreted mainly in the **bile**. Only a small fraction (approx. 2–5%) is excreted unchanged in the urine. Therefore, its pharmacokinetics are not significantly altered by declining renal function, making it safe to use at standard doses in patients with renal failure. **Why the other options are incorrect:** * **Vancomycin:** It is almost exclusively excreted by glomerular filtration. In renal failure, it can accumulate rapidly, leading to nephrotoxicity and ototoxicity. Dosing must be adjusted based on creatinine clearance and serum drug monitoring. * **Ethambutol:** About 80% of the drug is excreted unchanged in the urine. Accumulation in renal failure can lead to **optic neuritis**, a classic side effect. * **Ciprofloxacin:** This fluoroquinolone is eliminated via both renal (tubular secretion and filtration) and hepatic routes. In patients with a GFR < 30 ml/min, the dose must be reduced. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for antibiotics safe in renal failure:** "**D**on't **C**hange **M**edicine **E**verytime" (**D**oxycycline, **C**eftriaxone/Chloramphenicol, **M**acrolides/Metronidazole, **E**rythromycin). * **Doxycycline** is the tetracycline of choice in renal failure because it is excreted via the gut. * **Ceftriaxone** is primarily eliminated via biliary excretion, requiring no adjustment unless there is concurrent hepatic impairment.

Q: First-pass metabolism is a significant problem for drugs administered via which route?

Oral route (directly into stomach). **Explanation:** **1. Why the Oral Route is Correct:** The **Oral route** is the most common route associated with significant **First-pass metabolism** (Presystemic metabolism). When a drug is swallowed, it is absorbed from the gastrointestinal tract into the **portal venous system**. Before reaching the systemic circulation, the drug must pass through the **liver**, which is the primary site for drug metabolism. If the liver has a high extraction ratio for a specific drug, a large fraction of the dose is inactivated before it can reach its target site, significantly reducing its **bioavailability**. **2. Analysis of Incorrect Options:** * **Sublingual route:** Drugs absorbed through the buccal mucosa drain directly into the superior vena cava, bypassing the portal circulation and the liver. This is why Nitroglycerin is given sublingually for rapid action. * **Rectal route:** The rectal venous drainage is divided. The lower part bypasses the liver, while the upper part enters the portal system. Thus, it only partially avoids first-pass metabolism (roughly 50%). * **Intramuscular route:** This is a parenteral route where the drug is absorbed directly into the systemic capillaries, completely bypassing the gastrointestinal tract and the first pass through the liver. **3. NEET-PG High-Yield Pearls:** * **Bioavailability (F):** For intravenous (IV) administration, F = 100%. For oral drugs with high first-pass metabolism (e.g., Propranolol, Lidocaine, Morphine, Nitroglycerin), F is significantly low. * **Lidocaine:** It has such high first-pass metabolism that it is practically ineffective when given orally; hence, it is used parenterally as an anti-arrhythmic. * **Propranolol:** Shows significant individual variation in oral bioavailability due to first-pass effects, requiring much higher oral doses compared to IV doses.

Q: What fraction of an administered drug dose reaches the systemic circulation unchanged?

Bioavailability. **Explanation:** **Bioavailability (Option C)** is defined as the fraction (or percentage) of an administered dose of unchanged drug that reaches the systemic circulation. When a drug is given intravenously, its bioavailability is 100% ($f = 1$). For extravascular routes (like oral), bioavailability is often less than 100% due to incomplete absorption and the **first-pass metabolism** in the gut wall or liver. **Why other options are incorrect:** * **Half-life (Option A):** This is a temporal parameter. It is the time required for the plasma concentration of a drug to reduce by 50%. It determines the dosing interval and the time to reach steady state. * **Absorption (Option B):** This is the movement of a drug from its site of administration into the bloodstream. While absorption is a component of bioavailability, it does not account for the "unchanged" fraction that survives first-pass metabolism. * **Elimination (Option D):** This refers to the irreversible removal of the drug from the body via excretion (e.g., kidneys) or metabolic biotransformation (e.g., liver). **NEET-PG High-Yield Pearls:** 1. **Bioequivalence:** Two pharmaceutical products are bioequivalent if their bioavailability (AUC, $C_{max}$, and $T_{max}$) is not significantly different when given at the same dose. 2. **Area Under the Curve (AUC):** Bioavailability is calculated by comparing the AUC of an oral dose to the AUC of an IV dose ($F = \frac{AUC_{oral}}{AUC_{IV}}$). 3. **First-pass effect:** Drugs with high first-pass metabolism (e.g., Nitroglycerin, Propranolol, Lidocaine) have very low oral bioavailability and are typically given via alternative routes.

Q: All of the following drugs are metabolized by acetylation, except?

Ketoconazole. **Explanation:** The question tests your knowledge of **Phase II metabolic reactions**, specifically **Acetylation**. This pathway is catalyzed by the enzyme *N-acetyltransferase* (NAT) in the liver. **Why Ketoconazole is the correct answer:** Ketoconazole is an imidazole antifungal that is primarily metabolized in the liver via **Oxidation** (Phase I reaction) through the **CYP3A4** enzyme system. It does not undergo acetylation. Notably, Ketoconazole is a potent inhibitor of CYP3A4, leading to numerous drug-drug interactions. **Analysis of Incorrect Options (Drugs that undergo Acetylation):** A classic mnemonic to remember drugs metabolized by acetylation is **"SHIP"**: * **S – Sulfonamides:** Used in various bacterial infections; their acetylated metabolites can sometimes cause crystalluria. * **H – Hydralazine:** An antihypertensive used in pregnancy-induced hypertension and heart failure. * **I – Isoniazid (INH):** A primary anti-tubercular drug. * **P – Procainamide:** A Class 1A antiarrhythmic. **High-Yield Clinical Pearls for NEET-PG:** 1. **Genetic Polymorphism:** Acetylation shows bimodal distribution in the population. Individuals are classified as **Fast Acetylators** or **Slow Acetylators**. 2. **Slow Acetylators:** These individuals are at a higher risk of drug-induced toxicity. Specifically, they are prone to **Drug-Induced Lupus Erythematosus (DILE)** when taking Hydralazine, Procainamide, or Isoniazid. 3. **Isoniazid Toxicity:** In slow acetylators, INH can cause peripheral neuropathy (due to Vitamin B6 deficiency), whereas fast acetylators may be more prone to INH-induced hepatotoxicity due to rapid conversion to acetylhydrazine.

Q: Pharmacodynamics includes which of the following?

Mechanism of action. **Explanation:** Pharmacology is broadly divided into two main branches: **Pharmacokinetics** and **Pharmacodynamics**. To differentiate them easily, remember: Pharmacodynamics is **"what the drug does to the body,"** while Pharmacokinetics is **"what the body does to the drug."** **1. Why "Mechanism of Action" is Correct:** Pharmacodynamics deals with the biochemical and physiological effects of drugs and their mechanisms of action. This includes drug-receptor interactions, signal transduction pathways, and the resulting biological effect (e.g., a beta-blocker binding to $\beta_1$ receptors to decrease heart rate). **2. Why Other Options are Incorrect:** Options A, B, and C are components of **Pharmacokinetics**. Pharmacokinetics is traditionally described by the acronym **ADME**: * **Absorption (C):** Movement of the drug from the site of administration into the bloodstream. * **Distribution:** Movement of the drug from the blood into various tissues. * **Metabolism (Biotransformation):** Chemical alteration of the drug in the body (primarily in the liver). * **Excretion (B) / Elimination (A):** The process by which the drug or its metabolites are removed from the body (primarily via kidneys). **High-Yield Clinical Pearls for NEET-PG:** * **Receptor Types:** Most drugs act through receptors (G-Protein Coupled Receptors are the largest family). * **Potency vs. Efficacy:** **Efficacy** (the maximum response a drug can produce) is clinically more important than **Potency** (the amount of drug needed to produce an effect). * **Therapeutic Index (TI):** A pharmacodynamic parameter calculated as $LD_{50} / ED_{50}$. A higher TI indicates a safer drug (e.g., Penicillin), while a narrow TI requires therapeutic drug monitoring (e.g., Lithium, Digoxin, Warfarin).

Q: Which of the following statements is true about steady state?

Rate of administration is equal to rate of elimination.. ### Explanation **1. Why Option A is Correct:** Steady state (Css) is a pharmacokinetic condition where the **rate of drug administration (input) equals the rate of drug elimination (output)**. At this point, the total amount of drug in the body remains constant, and the plasma concentration fluctuates within a stable range. Mathematically, it is represented as: *Rate of Infusion ($R_0$) = Clearance ($CL$) × Steady State Concentration ($C_{ss}$)*. **2. Analysis of Incorrect Options:** * **Option B:** This is incorrect because the time taken to reach steady state depends **solely on the half-life ($t_{1/2}$)** of the drug. It is independent of the dose or frequency of administration. * **Option C:** This is incorrect because the **magnitude** (level) of the plasma concentration at steady state is directly proportional to the dose rate. While the *time* to reach it is constant, a higher dose results in a higher steady-state concentration. * **Option D:** This is incorrect. A longer dosing interval allows more time for the drug to be eliminated between doses, leading to a **greater** fluctuation (wider gap) between peak ($C_{max}$) and trough ($C_{min}$) levels. **3. High-Yield Clinical Pearls for NEET-PG:** * **Rule of 4-5:** It takes approximately **4 to 5 half-lives** to reach steady state (94% at 4 $t_{1/2}$; 97% at 5 $t_{1/2}$). * **Loading Dose:** If clinical urgency requires reaching steady state immediately, a **Loading Dose** is given. However, even with a loading dose, the "true" steady state of the body is only maintained after 4-5 half-lives. * **Elimination:** Similarly, it takes 4-5 half-lives for a drug to be completely eliminated from the body after stopping the infusion.

Q: Sulphonamide is conjugated with which of the following processes?

Acetylation. **Explanation:** **1. Why Acetylation is Correct:** Sulphonamides undergo Phase II metabolism, primarily through **Acetylation** in the liver. This process is catalyzed by the enzyme **N-acetyltransferase (NAT)**. Unlike most metabolic processes that increase water solubility, the acetylated metabolites of certain older sulphonamides (like Sulfadiazine) are less soluble in acidic urine. This can lead to the formation of crystals in the renal tubules, a condition known as **crystalluria**. **2. Why the Other Options are Incorrect:** * **Methylation:** This is a Phase II reaction used for drugs like adrenaline, histamine, and dopamine (via COMT), but it is not the primary pathway for sulphonamides. * **Hydroxylation:** This is a Phase I reaction (oxidation) typically involving the Cytochrome P450 system. While some drugs undergo both Phase I and Phase II, the definitive metabolic hallmark for sulphonamides is Phase II conjugation via acetylation. **3. NEET-PG High-Yield Pearls:** * **Genetic Polymorphism:** Acetylation exhibits genetic polymorphism, categorizing individuals into **"Fast Acetylators"** and **"Slow Acetylators."** Slow acetylators are at a higher risk of toxicity from drugs like Isoniazid (peripheral neuropathy), Hydralazine, and Procainamide (Drug-induced Lupus). * **Mnemonic for Acetylation:** Remember **"SHIP"** — **S**ulphonamides, **H**ydralazine, **I**soniazid, and **P**rocainamide. * **Clinical Tip:** To prevent sulphonamide-induced crystalluria, patients are advised to increase fluid intake and undergo **urinary alkalinization** (as the acetylated metabolite is more soluble in alkaline pH).

Q: Which is the most common phase-2 reaction in drug metabolism?

Glucuronide conjugation. Drug metabolism (biotransformation) typically occurs in two phases. Phase-1 (Non-synthetic) involves oxidation, reduction, and hydrolysis, while Phase-2 (Synthetic) involves conjugation reactions to make the drug more water-soluble for excretion [4]. **1. Why Glucuronide Conjugation is Correct:** Glucuronidation is the **most common and most important** Phase-2 reaction [2]. It is mediated by the enzyme **UDP-glucuronosyltransferase (UGT)**. Its dominance is due to the high availability of the substrate (glucuronic acid, derived from glucose) and the wide variety of functional groups (hydroxyl, carboxyl, amino) it can bind to [3]. Most drugs, including morphine, paracetamol, and lorazepam, undergo this process. **2. Analysis of Incorrect Options:** * **Acetylation (B):** Common for drugs like Isoniazid, Hydralazine, and Procainamide (remembered by the mnemonic **SHIP**). It is clinically significant due to genetic polymorphism (fast vs. slow acetylators) but is not the most frequent reaction. * **Methylation (C):** A relatively minor pathway involving enzymes like COMT (for catecholamines) or TPMT (for thiopurines). * **Sulfate Conjugation (D):** Important for steroids and phenolic compounds, but the body has a limited pool of sulfate, making it less common than glucuronidation [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Exception to the Rule:** Most Phase-2 reactions result in inactivation, but **Morphine-6-glucuronide** is a potent active metabolite. * **Microsomal vs. Non-microsomal:** Glucuronidation is the **only** Phase-2 reaction carried out by microsomal enzymes; all other Phase-2 reactions are non-microsomal (cytosolic). * **Neonatal Physiology:** Newborns are deficient in glucuronyltransferase, leading to "Gray Baby Syndrome" when given Chloramphenicol.

Q: Which receptor/transduction mechanism acts the fastest?

Intrinsic ion channel operation. **Explanation:** The speed of a receptor’s response is determined by the complexity of its signaling cascade. **1. Why "Intrinsic Ion Channel Operation" is correct:** These are **Ionotropic receptors** (e.g., Nicotinic ACh, GABA-A, NMDA receptors). The receptor itself is an ion channel. Upon ligand binding, the channel undergoes a conformational change and opens immediately, allowing ions to flow across the membrane. This process occurs in **milliseconds**, making it the fastest transduction mechanism in the body. It is essential for rapid neurotransmission and muscle contraction. **2. Why the other options are incorrect:** * **A & B (GPCR Pathways):** These involve **Metabotropic receptors**. They require multiple steps: ligand binding → G-protein activation → effector enzyme activation (Adenylyl cyclase or Phospholipase C) → second messenger generation (cAMP or IP3/DAG). This cascade takes **seconds**. * **D (Nuclear Receptors):** These are the slowest. They involve ligand-receptor translocation to the nucleus, binding to DNA, gene transcription, and protein synthesis. This process takes **hours to days** (e.g., Steroids, Thyroid hormones). **NEET-PG High-Yield Pearls:** * **Fastest:** Ionotropic receptors (Milliseconds). * **Slowest:** Nuclear/Gene transcription receptors (Hours/Days). * **Intermediate:** GPCRs (Seconds) and Enzyme-linked receptors (e.g., Insulin - Minutes). * **Location Tip:** Nuclear receptors for Steroids are usually **cytoplasmic**, while those for Thyroid hormones are **permanently in the nucleus**.

Question 1

A young male presents with severe asthma. The pharmacokinetics of theophylline include the following parameters: Vd = 35 L; CL = 48 mL/min; half-life = 8 hours. If an intravenous infusion of theophylline is started at a rate of 0.48 mg/min, how long will it take to reach 93.75% of the steady state concentration?

Accepted Answer

Approximately 32 hours

Answer

Approximately 48 minutes

Answer

Approximately 5.8 hours

Answer

Approximately 8 hours

Question 2

The dose of which antibiotic need not be altered in renal failure?

Accepted Answer

Erythromycin

Answer

Vancomycin

Answer

Ethambutol

Answer

Ciprofloxacin

Question 3

First-pass metabolism is a significant problem for drugs administered via which route?

Accepted Answer

Oral route (directly into stomach)

Answer

Sublingual route

Answer

Rectal route

Answer

Intramuscular route

Question 4

What fraction of an administered drug dose reaches the systemic circulation unchanged?

Accepted Answer

Bioavailability

Answer

Half-life

Answer

Absorption

Answer

Elimination

Question 5

All of the following drugs are metabolized by acetylation, except?

Accepted Answer

Ketoconazole

Answer

Isoniazid (INH)

Answer

Sulfonamides

Answer

Hydralazine

Question 6

Pharmacodynamics includes which of the following?

Accepted Answer

Mechanism of action

Answer

Drug elimination

Answer

Drug excretion

Answer

Drug absorption

Question 7

Which of the following statements is true about steady state?

Accepted Answer

Rate of administration is equal to rate of elimination.

Answer

It does not depend upon half-life.

Answer

Plasma concentration achieved is independent of dose rate.

Answer

The longer the dosing interval, the lesser the difference between peak and trough values.

Question 8

Sulphonamide is conjugated with which of the following processes?

Accepted Answer

Acetylation

Answer

Methylation

Answer

Hydroxylation

Answer

None of the above

Question 9

Which is the most common phase-2 reaction in drug metabolism?

Accepted Answer

Glucuronide conjugation

Answer

Acetylation

Answer

Methylation

Answer

Sulfate conjugation

Question 10

Which receptor/transduction mechanism acts the fastest?

Accepted Answer

Intrinsic ion channel operation

Answer

Adenylyl cyclase – cyclic AMP pathway

Answer

Phospholipase C–IP3 : DAG pathway

Answer

Nuclear receptors

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?